ASX:MGH
ASX:MGHConstruction

ASX Stocks Priced Below Intrinsic Value Estimates Include Guzman y Gomez And Two More

The Australian stock market has shown resilience, with the ASX200 gaining 10% over the past ten months, despite a relatively uneventful September. Recent developments in critical minerals and healthcare have sparked investor interest, highlighting opportunities for stocks priced below their intrinsic value estimates. In this context, identifying undervalued stocks requires a keen understanding of market trends and potential catalysts like geopolitical shifts or sector-specific growth drivers.
ASX:MAH
ASX:MAHMetals and Mining

3 Undiscovered Australian Gems with Promising Potential

The Australian market has shown resilience, with the ASX200 climbing 10% over the past ten months, driven in part by renewed interest in critical minerals as geopolitical tensions influence global supply dynamics. In this environment, identifying stocks with strong fundamentals and strategic positioning in emerging sectors like rare earths and healthcare can offer intriguing opportunities for investors seeking to navigate these evolving market conditions.
ASX:WGN
ASX:WGNBasic Materials

ASX Penny Stocks To Watch In October 2025

The Australian market has seen a steady rise, with the ASX200 up 10% over the past ten months, driven in part by renewed interest in critical minerals due to geopolitical tensions. While penny stocks might sound like a term from trading days gone by, they still represent an intriguing segment for investors seeking growth opportunities. These smaller or newer companies can offer significant potential when backed by solid financials, and this article highlights three such stocks that could...
ASX:BOQ
ASX:BOQBanks

Bank of Queensland (ASX:BOQ) Valuation in Focus After Declining Full-Year Earnings

The Bank of Queensland (ASX:BOQ) released its full-year results, showing net income and earnings per share down from last year. This earnings announcement comes just before the bank’s upcoming quarterly call, drawing close investor focus. See our latest analysis for Bank of Queensland. Shares of Bank of Queensland have seen some ups and downs lately, with a mild 1-month share price return of 0.6% but a steeper 8.1% decline over the past three months as the market digested weaker earnings...
ASX:AGI
ASX:AGIHospitality

Discover 3 ASX Penny Stocks With Market Caps Under A$2B

Australian shares are showing resilience, with the ASX rallying despite recent volatility in global markets influenced by U.S. political and economic concerns. For investors looking beyond the major players, penny stocks—often representing smaller or emerging companies—can still offer intriguing potential for growth. While the term "penny stock" may seem outdated, these investments can uncover hidden value when backed by solid financial health, and we'll explore three such opportunities on...
ASX:ABB
ASX:ABBTelecom

Aussie Broadband (ASX:ABB): Evaluating Valuation After FY26 Guidance Shifts and Bullish Broker Outlook

Aussie Broadband (ASX:ABB) shares slipped 1.5% after a trading update revealed that FY26 growth forecasts fell short of market expectations, sparking a swift reaction among investors and industry watchers. See our latest analysis for Aussie Broadband. Despite the short-term wobble following its cautious FY26 outlook, Aussie Broadband’s share price is still up an impressive 58% so far this year, and its three-year total shareholder return has soared over 150%. Recent volatility mainly reflects...
ASX:CU6
ASX:CU6Pharmaceuticals

Clarity Pharmaceuticals (ASX:CU6) Is Down 5.2% After PSMA Imaging Trial Hits Primary Endpoint Has The Bull Case Changed?

Clarity Pharmaceuticals recently announced that its Co-PSMA Investigator-Initiated Trial led by St Vincent's Hospital Sydney achieved its primary endpoint, with 64Cu-SAR-bisPSMA detecting a statistically significant higher number of prostate cancer lesions in patients with low PSA compared to the standard-of-care PET/CT imaging. This outcome highlights the potential for 64Cu-SAR-bisPSMA to improve early detection and staging of prostate cancer, addressing a significant clinical need within...
ASX:VNT
ASX:VNTConstruction

A Look at Ventia (ASX:VNT) Valuation Following $935m Australian Defence Force Contract Win

Ventia Services Group (ASX:VNT) just landed a substantial $935 million contract to deliver clothing capability services to the Australian Defence Force, with services set to begin in May 2026. This move strengthens Ventia’s long-term sector positioning and revenue outlook. See our latest analysis for Ventia Services Group. Ventia’s latest Defence Force win arrives on the back of strong share price momentum, with the stock delivering a 48.75% year-to-date price return and a stellar 139% total...